Business UpdateJul 15, 2026, 01:01 AM
Molecular Partners Advances Multispecific Radio-DARPins for Cancer Therapy
AI Summary
Molecular Partners highlighted its innovative approach to overcoming target limitations in radioligand therapy (RLT) through multispecific Radio-DARPins at the Gordon Research Conference. The company is developing these bispecific Radio-DARPins to engage multiple tumor targets simultaneously, aiming to improve precision and therapeutic efficacy for heterogeneous cancers. Molecular Partners' lead candidate MP0712 is currently in a Phase 1/2a trial, with MP0726 expected to begin human imaging this year, and a third program anticipated in 2026.
Key Highlights
- Molecular Partners presented on multispecific Radio-DARPins at the Gordon Research Conference.
- The presentation highlighted the ability of DARPins to optimize binding properties, half-life, and biodistribution.
- Company is developing multispecific Radio-DARPins to engage multiple tumor targets simultaneously.
- Lead Radio-DARPin candidate MP0712 is in a multicenter US Phase 1/2a trial.
- Second candidate MP0726 is expected to begin human imaging this year.
- A third Radio-DARPin program, targeting a different tumor, is expected in 2026.
Price Impact
More from MOLN